Ardelyx presents additional data at 2024 DDW conference on IBSRELA

Ardelyx announced that data supporting additional positive clinical observations of IBSRELA was presented at the 2024 Digestive Disease Week Conference, DDW, currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment that is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation, IBS-C, in adults. “We are thrilled to share new data on the safety and efficacy of IBSRELA in adults with IBS-C at this year’s DDW Conference as we seek to continually elucidate its potential benefit in this patient population. These data provide additional information for both patients and prescribers as they consider IBSRELA as a potential new treatment option when symptoms of IBS-C persist despite current therapies,” said Laura Williams, MD MPH, chief medical officer of Ardelyx. “These analyses provide further evidence of the role IBSRELA could play, with its novel mechanism of action, in the treatment of IBS-C.”